Abstract Background Protein–protein interactions (PPIs) are fundamental to the growth and survival of cells and serve as excellent targets to develop inhibitors of biological processes such as host-pathogen interactions and cancer cell proliferation. However, isolation of PPI inhibitors is extremely challenging. While several in vitro assays to screen for PPI inhibitors are available, they are often expensive, cumbersome, and require large amounts of purified protein. In contrast, limited in vivo assays are available to screen for small-molecule inhibitors of PPI. Methods We have engineered a yeast strain that is suitable for screening of small-molecule inhibitors of protein-protein interaction using the Yeast 2-hybrid Assay. We have optimi...
Protein–protein interactions play a central role in signal transduction, transcription regulations, ...
A modified yeast one-hybrid (MY1H) system has been developed for in vivo investigation of simultaneo...
Protein-protein interactions (PPIs) constitute an emerging class of targets for the next generation ...
Background: Protein–protein interactions (PPIs) are fundamental to the growth and survival of cells ...
The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understand...
Yeast has proven to be an efficient model system for functional and pharmacological studies of the p...
In this work, the yeast Saccharomyces cerevisiae was used to individually study human p53, p63 (full...
AbstractThe p53 binding protein, termed p53BP2, was identified as a protein interacting with protein...
The p53 protein, also known as the “guardian of the genome”, has an important role in the tumor supp...
The development of protein–protein interaction (PPI) inhibitors with therapeutic value is of increas...
The p53-MDM2 interaction is a well-known protein-protein contact, and its disruption is a key event ...
It is widely accepted that the MDM2 oncoprotein is an inhibitor of the p53 tumor suppressor, via the...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Protein–protein interactions play a central role in signal transduction, transcription regulations, ...
A modified yeast one-hybrid (MY1H) system has been developed for in vivo investigation of simultaneo...
Protein-protein interactions (PPIs) constitute an emerging class of targets for the next generation ...
Background: Protein–protein interactions (PPIs) are fundamental to the growth and survival of cells ...
The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understand...
Yeast has proven to be an efficient model system for functional and pharmacological studies of the p...
In this work, the yeast Saccharomyces cerevisiae was used to individually study human p53, p63 (full...
AbstractThe p53 binding protein, termed p53BP2, was identified as a protein interacting with protein...
The p53 protein, also known as the “guardian of the genome”, has an important role in the tumor supp...
The development of protein–protein interaction (PPI) inhibitors with therapeutic value is of increas...
The p53-MDM2 interaction is a well-known protein-protein contact, and its disruption is a key event ...
It is widely accepted that the MDM2 oncoprotein is an inhibitor of the p53 tumor suppressor, via the...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Protein–protein interactions play a central role in signal transduction, transcription regulations, ...
A modified yeast one-hybrid (MY1H) system has been developed for in vivo investigation of simultaneo...
Protein-protein interactions (PPIs) constitute an emerging class of targets for the next generation ...